Darbepoetin alfa and chronic kidney disease [4]

New England Journal of Medicine

Volumn 362, Issue 7, 2010, Pages 654-655

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a   Casartelli, Donatella ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; LETTER; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; STROKE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; FEMALE; MALE; NOTE; TREATMENT OUTCOME; BLOOD; METABOLISM; RENAL REPLACEMENT THERAPY; RISK; THROMBOCYTE COUNT;

ANEMIA; DIABETES MELLITUS, TYPE 2; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; NEOPLASMS; RENAL INSUFFICIENCY, CHRONIC; STROKE; TREATMENT OUTCOME; PLATELET COUNT; RENAL DIALYSIS; RISK;

EID: 77149160085     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. FDA strengthens boxed warnings, approves 1. other safety labeling changes for erythropoiesis-stimulating agents. Silver Spring, MD: Food and Drug Administration, November 8, 2007. (Accessed January 28, 2010, at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109024.htm.)